Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Human obesity has become a global health epidemic, with few safe and effective pharmacological therapies currently available. The systemic loss of ovarian estradiol (E2) in women after menopause greatly increases the risk of obesity and metabolic dysfunction, revealing the critical role of E2 in this setting. The salutary effects of E2 are traditionally attributed to the classical estrogen receptors ERα and ERβ, with the contribution of the G protein–coupled estrogen receptor (GPER) still largely unknown. Here, we used ovariectomy- and diet-induced obesity (DIO) mouse models to evaluate the preclinical activity of GPER-selective small-molecule agonist G-1 (also called Tespria) against obesity and metabolic dysfunction. G-1 treatment of ovariectomized female mice (a model of postmenopausal obesity) reduced body weight and improved glucose homeostasis without changes in food intake, fuel source usage, or locomotor activity. G-1–treated female mice also exhibited increased energy expenditure, lower body fat content, and reduced fasting cholesterol, glucose, insulin, and inflammatory markers but did not display feminizing effects on the uterus (imbibition) or beneficial effects on bone health. G-1 treatment of DIO male mice did not elicit weight loss but prevented further weight gain and improved glucose tolerance, indicating that G-1 improved glucose homeostasis independently of its antiobesity effects. However, in ovariectomized DIO female mice, G-1 continued to elicit weight loss, reflecting possible sex differences in the mechanisms of G-1 action. In conclusion, this work demonstrates that GPER-selective agonism is a viable therapeutic approach against obesity, diabetes, and associated metabolic abnormalities in multiple preclinical male and female models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Obesity Among Adults in the United States, 2005 to 2014
Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016) · JAMA · doi:10.1001/jama.2016.6458 · Cited by 2,803
A transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302
Self-citationAdipose tissue dysfunction as determinant of obesity-associated metabolic complications
Longo, M., Zatterale, F., Naderi, J., Parrillo, L., Formisano, P., Raciti, G. A., Beguinot, F., & Miele, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092358 · Cited by 1,575 · cited 1×
“Rodents and primates, including humans, with increased body weight exhibit low-grade chronic inflammation in their WAT and other tissues due in part to ectopic fat deposition (65).”
BackgroundIncreased adipose tissue in male and female estrogen receptor-α knockout mice
Heine, P. A., Taylor, J. A., Iwamoto, G. A., Lubahn, D. B., & Cooke, P. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12729 · Cited by 1,282
Sex differences in metabolic homeostasis, diabetes, and obesity
Mauvais-Jarvis, F. (2015) · Biology of Sex Differences · doi:10.1186/s13293-015-0033-y · Cited by 626 · cited 1×
“Thus, postmenopausal women exhibit an increased susceptibility to weight gain and associated metabolic dysfunction due to the loss of estrogenic protection, which can be ameliorated by E2 supplementation (14).”
BackgroundSelf-citationPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Estrogen deficiency and the origin of obesity during menopause
Lizcano, F., & Guzmán, G. (2014) · BioMed Research International · doi:10.1155/2014/757461 · Cited by 586
Gonadal Hormones Determine Sensitivity to Central Leptin and Insulin
Clegg, D. J., Brown, L. M., Woods, S. C., & Benoit, S. C. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1339 · Cited by 552 · cited 1×
“We also observed a reduction in circulating concentrations of leptin and resistin upon G-1 treatment, which may contribute to the overall increase in energy expenditure (56, 57) and improved glucose homeostasis (58).”
BackgroundEstrogen Receptors and the Metabolic Network
Barros, R. P. A., & Gustafsson, J.-Å. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.005 · Cited by 458 · cited 1×
“The metabolic effects of E2 have been largely attributed to the nuclear estrogen receptors and (ER and ER) that conventionally function as ligand-activated transcription factors (15), although rapid signaling in response to E2 has become recognized as critical to overall estrogenic activities (16–18).”
BackgroundRegulatory role of G protein-coupled estrogen receptor for vascular function and obesity
Haas, E., Bhattacharya, I., Brailoiu, E., Damjanović, M., Brailoiu, G. C., Gao, X., Mueller-Guerre, L., Marjon, N. A., Gut, A., Minotti, R., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.190892 · Cited by 373 · cited 2×
“RESULTS GPER activation reduces obesity resulting from estrogen deficiency Previous studies from our group (25, 33, 34) and other investigators (35) have shown that GPER deficiency in mice results in obesity with concomitant disturbances in glucose and lipid homeostasis, although one report has found the opposite (36).”
BackgroundSelf-citationAdaptive thermogenesis in humans
Rosenbaum, M., & Leibel, R. L. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.184 · Cited by 349 · cited 1×
“Unfortunately, “effective” marketed drugs only result in sustained weight loss of typically ~5%, even with patients adhering to strict diets, due in part to adaptive thermogenesis or metabolic adaptation (9).”
BackgroundRole of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue.
Yin, J., Gao, Z., He, Q., Zhou, D., Guo, Z., & Ye, J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90760.2008 · Cited by 319
Ribas, V., Nguyen, M. T. A., Henstridge, D. C., Nguyen, A.-K., Beaven, S. W., Watt, M. J., & Hevener, A. L. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00504.2009 · Cited by 309
Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence?
Lean, M. E. J., & Malkova, D. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.220 · Cited by 253
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232 · cited 1×
“Thus, it is imperative to identify targets, pathways, and drug classes to treat obesity and its associated complications (10).”
BackgroundSharma, G., Hu, C., Brigman, J. L., Zhu, G., Hathaway, H. J., & Prossnitz, E. R. (2013) · Endocrinology · doi:10.1210/en.2013-1357 · Cited by 210
Self-citationHypoxia and Adipocyte Physiology: Implications for Adipose Tissue Dysfunction in Obesity
Trayhurn, P. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161156 · Cited by 194 · cited 4×
“5 of 14 co activator 1 (PGC) (Ppargc1a; a regulator of cellular energy metabolism), peroxisomal acyl–coenzyme A (co-A) oxidase (Acox1; which catalyzes fatty acid -oxidation), hypoxia-inducible factor 1 (Hif1a), and vascular endothelial growth factor A (Vegfa), the latter two being important mediators of angiogen…”
BackgroundMethodInfluentialNaaz, A., Zakroczymski, M., Heine, P., Taylor, J., Saunders, P., Lubahn, D., & Cooke, P. S. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-38259 · Cited by 188
Respiration uncoupling and metabolism in the control of energy expenditure
Ricquier, D. (2005) · Proceedings of The Nutrition Society · doi:10.1079/pns2004408 · Cited by 175
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159
What have we learned about GPER function in physiology and disease from knockout mice
Prossnitz, E. R., & Hathaway, H. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.06.014 · Cited by 157
Self-citationLudgero-Correia, A., Aguila, M. B., Mandarim-de-Lacerda, C. A., & Faria, T. S. (2012) · Nutrition · doi:10.1016/j.nut.2011.07.014 · Cited by 121
Cited by
The G protein-coupled oestrogen receptor GPER in health and disease: an update
Prossnitz, E. R., & Barton, M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00822-7 · Cited by 231
Self-citationG protein-coupled estrogen receptor in immune cells and its role in immune-related diseases
Notas, G., Kampa, M., & Castanas, E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.579420 · Cited by 109
“Interestingly, another mechanism GPER1 affects diabetes and hypercholesterolemia, is a direct action on lipid metabolism (84) and insulin signaling (84, 85).”
BackgroundTargeting the G protein-coupled estrogen receptor (GPER) in obesity and diabetes
Sharma, G., & Prossnitz, E. R. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100080 · Cited by 34
Self-citationLiu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07005-0 · Cited by 13
“In high-fat diet-induced obesity models, the GPER agonist G1 reduces body weight and improves insulin sensitivity, highlighting its endocrine-mediated metabolic role [31, 74].”
Influential
Metadata
- Authors
- Sharma, G., Hu, C., Staquicini, D. I., Brigman, J. L., Liu, M., Mauvais-Jarvis, F., Pasqualini, R., Arap, W., Arterburn, J. B., Hathaway, H. J., & Prossnitz, E. R.
- Venue
- Science Translational Medicine
- Published
- 2020-01-29
- Volume
- 12
- Issue
- 528
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3003989813
- Cited by
- 105
- References
- 22
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.